EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
+1.88%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$6.75B
AUM Growth
+$6.75B
(+4.6%)
Cap. Flow
+$463M
Cap. Flow
% of AUM
6.86%
Top 10 Holdings %
Top 10 Hldgs %
24.03%
Holding
179
New
20
Increased
67
Reduced
21
Closed
18
Top Buys
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$65.6M |
| 2 |
Entegris
ENTG
|
$60.2M |
| 3 |
TSMC
TSM
|
$50.5M |
| 4 |
Cullinan Oncology
CGEM
|
$49M |
| 5 |
Zymeworks
ZYME
|
$44.1M |
Top Sells
| 1 |
Ecolab
ECL
|
$49.8M |
| 2 |
Wayfair
W
|
$49M |
| 3 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
$41.8M |
| 4 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$23.8M |
| 5 |
CrowdStrike
CRWD
|
$20.3M |
Sector Composition
| 1 | Healthcare | 40.17% |
| 2 | Technology | 26.2% |
| 3 | Industrials | 11.22% |
| 4 | Consumer Discretionary | 7.43% |
| 5 | Communication Services | 4.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Palo Alto Networks
PANW
$128B
| $48.1M | 0.71% |
149,237
+714
| +0.5% | +$230K |
|
|
TPTX
52
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $47.8M | 0.71% |
505,000
-78,000
| -13% | -$7.38M |
|
53
Neurocrine Biosciences
NBIX
$13.5B
| $46.1M | 0.68% |
474,000
+121,000
| +34% | +$11.8M |
|
54
Brookfield Renewable
BEPC
$5.92B
| $45.8M | 0.68% |
978,357
+510,957
| +109% | +$23.9M |
|
55
Kura Oncology
KURA
$732M
| $45.7M | 0.68% |
1,617,573
+557,573
| +53% | +$15.8M |
|
56
Syndax Pharmaceuticals
SNDX
$1.39B
| $45.1M | 0.67% |
2,016,993
+70,993
| +4% | +$1.59M |
|
|
BPMC
57
DELISTED
Blueprint Medicines
BPMC
| $44.9M | 0.67% |
462,000
| – | – |
|
|
58
Zymeworks
ZYME
$1.07B
| $44.1M | 0.65% |
+1,397,954
| New | +$44.1M |
|
59
BridgeBio Pharma
BBIO
$9.91B
| $43.9M | 0.65% |
+712,197
| New | +$43.9M |
|
60
Celldex Therapeutics
CLDX
$1.57B
| $42.5M | 0.63% |
2,062,433
+225,325
| +12% | +$4.64M |
|
61
Immunovant
IMVT
$2.91B
| $39.7M | 0.59% |
2,473,000
+1,541,000
| +165% | +$24.7M |
|
62
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$3.46B
| $39.3M | 0.58% |
700,200
-132,000
| -16% | -$7.41M |
|
63
Datadog
DDOG
$46.2B
| $39.2M | 0.58% |
470,903
+3,500
| +0.7% | +$292K |
|
64
Nurix Therapeutics
NRIX
$723M
| $37.3M | 0.55% |
1,200,000
+150,000
| +14% | +$4.66M |
|
65
Novanta
NOVT
$4.05B
| $36.9M | 0.55% |
280,000
| – | – |
|
66
Clearway Energy Class C
CWEN
$3.38B
| $36.7M | 0.54% |
1,303,400
+56,100
| +4% | +$1.58M |
|
67
MediaAlpha
MAX
$613M
| $36.7M | 0.54% |
1,034,559
+972,948
| +1,579% | +$34.5M |
|
|
ALLK
68
DELISTED
Allakos
ALLK
| $36.4M | 0.54% |
317,000
| – | – |
|
69
Zentalis Pharmaceuticals
ZNTL
$123M
| $36.1M | 0.54% |
832,000
| – | – |
|
70
KalVista Pharmaceuticals
KALV
$713M
| $35.3M | 0.52% |
1,373,000
-307,000
| -18% | -$7.89M |
|
71
Veracyte
VCYT
$2.41B
| $35M | 0.52% |
651,000
-279,000
| -30% | -$15M |
|
72
89bio
ETNB
$1.37B
| $30M | 0.45% |
1,268,539
+399,539
| +46% | +$9.46M |
|
|
FRLN
73
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $29.8M | 0.44% |
2,485,656
| – | – |
|
74
Cognex
CGNX
$7.38B
| $29.8M | 0.44% |
359,000
| – | – |
|
75
Lennox International
LII
$19.1B
| $29.6M | 0.44% |
95,000
| – | – |
|